336 related articles for article (PubMed ID: 27697044)
1. Challenges and Persistent Questions in the Treatment of Trichomoniasis.
de Brum Vieira P; Tasca T; Secor WE
Curr Top Med Chem; 2017; 17(11):1249-1265. PubMed ID: 27697044
[TBL] [Abstract][Full Text] [Related]
2. A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.
Meites E; Gaydos CA; Hobbs MM; Kissinger P; Nyirjesy P; Schwebke JR; Secor WE; Sobel JD; Workowski KA
Clin Infect Dis; 2015 Dec; 61 Suppl 8(Suppl 8):S837-48. PubMed ID: 26602621
[TBL] [Abstract][Full Text] [Related]
3. Effects of SQ109 on Trichomonas vaginalis.
de Souza TG; Granado R; Benaim G; de Souza W; Benchimol M
Exp Parasitol; 2023 Jul; 250():108549. PubMed ID: 37196704
[TBL] [Abstract][Full Text] [Related]
4. Anti-Trichomonas vaginalis activity of chalcone and amino-analogues.
Trein MR; Rodrigues E Oliveira L; Rigo GV; Garcia MAR; Petro-Silveira B; da Silva Trentin D; Macedo AJ; Regasini LO; Tasca T
Parasitol Res; 2019 Feb; 118(2):607-615. PubMed ID: 30535524
[TBL] [Abstract][Full Text] [Related]
5. In vitro effect of octenidine dihydrochloride against Trichomonas vaginalis.
Küng E; Pietrzak J; Klaus C; Walochnik J
Int J Antimicrob Agents; 2016 Mar; 47(3):232-4. PubMed ID: 26899578
[TBL] [Abstract][Full Text] [Related]
6. Gold(I) Phosphine Derivatives with Improved Selectivity as Topically Active Drug Leads to Overcome 5-Nitroheterocyclic Drug Resistance in
Miyamoto Y; Aggarwal S; Celaje JJA; Ihara S; Ang J; Eremin DB; Land KM; Wrischnik LA; Zhang L; Fokin VV; Eckmann L
J Med Chem; 2021 May; 64(10):6608-6620. PubMed ID: 33974434
[No Abstract] [Full Text] [Related]
7. Mycoplasma hominis infection of Trichomonas vaginalis is not associated with metronidazole-resistant trichomoniasis in clinical isolates from the United States.
Butler SE; Augostini P; Secor WE
Parasitol Res; 2010 Sep; 107(4):1023-7. PubMed ID: 20652315
[TBL] [Abstract][Full Text] [Related]
8. Exploring novel pyrazole-nitroimidazole hybrids: Synthesis and antiprotozoal activity against the human pathogen trichomonas vaginalis.
Silva RC; De Freitas A; Vicente B; Midlej V; Dos Santos MS
Bioorg Med Chem; 2024 Mar; 102():117679. PubMed ID: 38461555
[TBL] [Abstract][Full Text] [Related]
9. Metronidazole resistance in Trichomonas vaginalis from highland women in Papua New Guinea.
Upcroft JA; Dunn LA; Wal T; Tabrizi S; Delgadillo-Correa MG; Johnson PJ; Garland S; Siba P; Upcroft P
Sex Health; 2009 Dec; 6(4):334-8. PubMed ID: 19917203
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic aspects of trichomoniasis].
Vukićević J; Jankicević J
Srp Arh Celok Lek; 2003; 131(3-4):156-61. PubMed ID: 14608880
[TBL] [Abstract][Full Text] [Related]
11. Antiparasitic activity of furanyl N-acylhydrazone derivatives against Trichomonas vaginalis: in vitro and in silico analyses.
Alves MSD; das Neves RN; Sena-Lopes Â; Domingues M; Casaril AM; Segatto NV; Nogueira TCM; de Souza MVN; Savegnago L; Seixas FK; Collares T; Borsuk S
Parasit Vectors; 2020 Feb; 13(1):59. PubMed ID: 32046788
[TBL] [Abstract][Full Text] [Related]
12. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.
Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE
Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623
[TBL] [Abstract][Full Text] [Related]
13. The clinical spectrum of Trichomonas vaginalis infection and challenges to management.
Muzny CA; Schwebke JR
Sex Transm Infect; 2013 Sep; 89(6):423-5. PubMed ID: 23543252
[TBL] [Abstract][Full Text] [Related]
14. Developing a new drug against trichomoniasis, new inhibitory compounds of the protein triosephosphate isomerase.
Vique-Sánchez JL; Caro-Gómez LA; Brieba LG; Benítez-Cardoza CG
Parasitol Int; 2020 Jun; 76():102086. PubMed ID: 32112829
[TBL] [Abstract][Full Text] [Related]
15. Drug repositioning for novel antitrichomonas from known antiprotozoan drugs using hierarchical screening.
Meneses-Marcel A; Marrero-Ponce Y; Ibáñez-Escribano A; Gómez-Barrio A; Escario JA; Barigye SJ; Terán E; García-Jacas CR; Machado-Tugores Y; Nogal-Ruiz JJ; Arán-Redó VJ
Future Med Chem; 2018 Apr; 10(8):863-878. PubMed ID: 29589477
[TBL] [Abstract][Full Text] [Related]
16. Anti-Trichomonas vaginalis activity and chemical analysis of metabolites produced by marine-associated fungi.
Senger FR; Campos-Silva R; Landell MF; Silva DB; Menezes CB; Rigo GV; Silva LN; Trentin DS; Macedo AJ; Tasca T
Parasitol Res; 2022 Mar; 121(3):981-989. PubMed ID: 35113221
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic options for the treatment of human trichomoniasis.
Küng E; Fürnkranz U; Walochnik J
Int J Antimicrob Agents; 2019 Feb; 53(2):116-127. PubMed ID: 30612993
[TBL] [Abstract][Full Text] [Related]
18. 20S Proteasome as a Drug Target in Trichomonas vaginalis.
O'Donoghue AJ; Bibo-Verdugo B; Miyamoto Y; Wang SC; Yang JZ; Zuill DE; Matsuka S; Jiang Z; Almaliti J; Caffrey CR; Gerwick WH; Eckmann L
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31451503
[TBL] [Abstract][Full Text] [Related]
19. Trichomoniasis and its treatment.
Nanda N; Michel RG; Kurdgelashvili G; Wendel KA
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):125-35. PubMed ID: 16441214
[TBL] [Abstract][Full Text] [Related]
20. Epinecidin-1: A marine fish antimicrobial peptide with therapeutic potential against Trichomonas vaginalis infection in mice.
Huang HN; Chuang CM; Chen JY; Chieh-Yu P
Peptides; 2019 Feb; 112():139-148. PubMed ID: 30552913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
